Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic virus with the potential to cause a
persistent infection, ultimately leading to cirrhosis and hepatocellular carcinoma. Over the …

Multiple new therapeutic approaches are currently being developed to achieve sustained,
off-treatment suppression of HBV, a persistent hepatotropic infection that kills~ 2,000 people …

Short-term administration of the entry inhibitor myrcludex-B (MyrB) has been shown to be
safe and effective in phase II studies in patients coinfected with hepatitis B virus (HBV) and …

Background & Aims Knowledge about the regulation of anti-HBV humoral immunity during
natural HBV infection is limited. We recently utilized dual fluorochrome-conjugated HBsAg to …

Chronic hepatitis B virus (HBV) infection is a major global health burden affecting around
257 million people worldwide. The consequences of chronic HBV infection include …

Cure from chronic HBV infection is rare with current therapies. Basic research has helped to
fundamentally improve our knowledge of the viral life cycle and virus-host interactions, and …

Hepatitis delta virus (HDV) requires hepatitis B virus (HBV) to complete its infection cycle
and causes severe hepatitis, with limited therapeutic options. To determine the prospect of T …

Highlights•Current anti-HBV therapy suppresses but does not cure HBV infection.•
Reconstitution of HBV-specific immunity is an essential step to attain HBV cure.•Engineering …

Hepatitis B virus (HBV) and alcohol abuse often contribute to the development of end-stage
liver disease. Alcohol abuse not only causes rapid progression of liver disease in HBV …

Background & Aims Antigen-specific immunotherapy is a promising strategy to treat HBV
infection and hepatocellular carcinoma (HCC). To facilitate killing of malignant and/or …